Table 1.
Cardiovascular pharmacological agents prescribed in stable CHD patients.
| Pharmacological molecules | Patient numbers | Proportion within each drug class % |
|---|---|---|
| Anti-platelet agents (n = 2031) | ||
| Aspirin alone | 234 | 11.5 |
| Aspirin–clopidogrel | 1797 | 88.4 |
| β-Blockers (n = 1494) | ||
| Atenolol | 566 | 37.8 |
| Metoprolol | 394 | 26.4 |
| Carvedilol | 178 | 11.9 |
| Bisoprolol | 139 | 9.3 |
| Nebivolol | 108 | 7.2 |
| Propanolol | 74 | 4.9 |
| Others | 35 | 2.3 |
| Angiotensin converting enzyme inhibitors (n = 1196) | ||
| Ramipril | 504 | 42.1 |
| Lisinopril | 243 | 20.3 |
| Perindopril | 131 | 10.9 |
| Enalapril | 147 | 12.3 |
| Captopril | 87 | 7.3 |
| Trandolapril | 54 | 4.5 |
| Others | 30 | 2.5 |
| Angiotensin receptor blockers (n = 712) | ||
| Losartan | 340 | 47.7 |
| Valsartan | 159 | 22.3 |
| Telmisartan | 106 | 14.9 |
| Candesartan | 70 | 9.8 |
| Others | 37 | 5.2 |
| Calcium channel blockers (n = 1023) | ||
| Amlodipine | 485 | 47.5 |
| Diltiazem | 298 | 29.1 |
| Verapamil | 97 | 9.5 |
| Nifedipine | 46 | 4.5 |
| Felodipine | 47 | 4.6 |
| Nicardipine | 23 | 2.2 |
| Others | 27 | 2.6 |
| Statins (n = 1457) | ||
| Atorvastatin | 726 | 49.8 |
| Simvastatin | 422 | 28.9 |
| Rosuvastatin | 267 | 18.3 |
| Others | 42 | 2.8 |
| Other lipid lowering (n = 170) | ||
| Fibrates | 71 | 41.7 |
| Niacin | 29 | 17.0 |
| Orlistat | 35 | 20.6 |
| Others | 35 | 20.6 |